Key Points
- Zimmer Biomet insider Chad Phipps sold 3,000 shares at an average price of $98.35, generating $295,050 and reducing his holdings by 4.4% to 65,231 shares.
- The company exceeded quarterly expectations, reporting $2.07 in adjusted earnings per share and $2.18 billion in revenue, while revenue increased 4.8% year over year. Management issued fiscal 2026 EPS guidance of $8.47–$8.59.
- Zimmer Biomet declared a quarterly dividend of $0.24 per share, equivalent to a 1.0% yield. Analysts maintain a consensus “Hold” rating with an average price target of $104.42.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company's stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Zimmer Biomet Trading Up 0.6%
Shares of Zimmer Biomet stock opened at $94.78 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $106.88. The stock's 50-day simple moving average is $95.33 and its 200 day simple moving average is $91.56. The stock has a market capitalization of $18.08 billion, a P/E ratio of 23.06, a P/E/G ratio of 1.78 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet's dividend payout ratio is presently 23.36%.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Brighton Jones LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC bought a new stake in shares of Zimmer Biomet during the 2nd quarter worth $232,000. United Bank grew its position in Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock worth $1,085,000 after acquiring an additional 1,153 shares in the last quarter. Federated Hermes Inc. raised its position in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock valued at $194,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC lifted its stake in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on ZBH. Truist Financial lifted their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a research note on Thursday, August 6th. Wall Street Zen downgraded Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Canaccord Genuity Group raised their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Weiss Ratings upgraded Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, August 4th. Finally, Zacks Research upgraded Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $104.42.
Get Our Latest Research Report on ZBH
Zimmer Biomet Company Profile
(
Get Free Report)
Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.
The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
